Overview

Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)

Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to confirm the clinical efficacy of epratuzumab in the treatment of subjects with Systemic Lupus Erythematosus (SLE).
Phase:
Phase 3
Details
Lead Sponsor:
UCB Pharma
Treatments:
Epratuzumab